Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) Non-Current Receivables (2016 - 2025)

Trinity Biotech's Non-Current Receivables history spans 17 years, with the latest figure at $10.9 million for Q2 2025.

  • On a quarterly basis, Non-Current Receivables fell 37.65% to $10.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $10.9 million, a 37.65% decrease, with the full-year FY2024 number at $16.1 million, up 15.57% from a year prior.
  • Non-Current Receivables hit $10.9 million in Q2 2025 for Trinity Biotech, down from $16.1 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for TRIB hit a ceiling of $21.2 million in Q3 2024 and a floor of $10.9 million in Q2 2025.
  • Historically, Non-Current Receivables has averaged $15.8 million across 5 years, with a median of $15.9 million in 2022.
  • Biggest five-year swings in Non-Current Receivables: skyrocketed 40.5% in 2024 and later crashed 37.65% in 2025.
  • Tracing TRIB's Non-Current Receivables over 5 years: stood at $16.1 million in 2021, then fell by 2.25% to $15.8 million in 2022, then dropped by 11.76% to $13.9 million in 2023, then rose by 15.57% to $16.1 million in 2024, then crashed by 32.19% to $10.9 million in 2025.
  • Business Quant data shows Non-Current Receivables for TRIB at $10.9 million in Q2 2025, $16.1 million in Q4 2024, and $21.2 million in Q3 2024.